Odyssean LLC’s Atrium Therapeutics RNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-21,233
Closed -$286K – 575
2026
Q2
$286K Buy
+21,233
New +$277K 0.05% 425

Other funds holding RNA

Odyssean LLC's RNA Position: Q3 2026 in Review

Odyssean LLC sold out of Atrium Therapeutics (RNA) in Q3 2026, closing a stake of 21,233 shares — an estimated $286K sold.

Odyssean LLC first reported a position in RNA in Q2 2026 and held it in 1 quarter. The position peaked at $286K in Q2 2026. 148 funds tracked by Wall St. Rank hold RNA as of Q3 2026.

  • Odyssean LLC reported no remaining Atrium Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Odyssean LLC sold 21,233 Atrium Therapeutics shares in Q3 2026, an estimated $286K.
  • Odyssean LLC first reported a position in Atrium Therapeutics in Q2 2026 and held it in 1 quarter.
  • Odyssean LLC's Atrium Therapeutics position peaked at $286K in Q2 2026.
  • 148 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q3 2026.

Based on Odyssean LLC's 13F filing for Q3 2026, filed 16 Nov 2026.